Adalvo is pleased to announce that the Pivotal BE Study for Empagliflozin/Metformin Tablets 12.5/1000mg has been successfully completed.
Our product has been developed based on the reference brand Synjardy 12.5mg/1000mg film-coated Tablets, which is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
The brand sold approximately $1.5bn globally in 2022, having a significant growth potential with Global 3Y CAGR at +19%, according to IQVIA.
Based on this successful development, we expect to be amongst the first companies to launch on Day-1, in all major markets.
The successful development of this product further highlights Adalvo's ability to offer difficult-to-make, high-value products to their partners.
As a company committed to their Metabolism/Endocrinology portfolio, Adalvo offers an array of dossiers and aims to assist our partners in overcoming any challenges that may arise with these mature products.
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
bruno.alves@adalvo.com - Brazil
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!